Skip to main content

Month: April 2026

Media Advisory: Air Canada to Present First Quarter 2026 Results

MONTREAL, April 16, 2026 (GLOBE NEWSWIRE) — Michael Rousseau, Air Canada President and Chief Executive Officer, John Di Bert, Executive Vice President and Chief Financial Officer, and Mark Galardo, Executive Vice President & Chief Commercial Officer and President, Cargo, will hold a conference call for analysts at 5:00 PM ET on Thursday, April 30, 2026, to present the first quarter 2026 results and be available for analysts’ questions. Following the analysts’ questions, John Di Bert and Pierre Houle, Vice President and Treasurer, will be available to answer questions from term loan B lenders and holders of Air Canada bonds. Media and the public may access this call on a listen-only basis. Details are as follows:  Date: Thursday, April 30, 2026       Time: 05:00 p.m. ET       Webcast: https://edge.media-server.com/mmc/p/npdvtsfi    Note:...

Continue reading

Atlantic International Reports Fourth Quarter and Full Year 2025 Results

ENGLEWOOD CLIFFS, N.J., April 16, 2026 (GLOBE NEWSWIRE) — Atlantic International Corp. (Nasdaq: ATLN), a global provider of outsourced services and workforce solutions, today reported financial results for the fourth quarter and full year ended December 31, 2025. Following the combination with Circle8 Group, Atlantic is evolving into a scaled, transatlantic workforce solutions platform with a pro forma revenue run-rate exceeding $1 billion, combining U.S. industrial staffing operations with high-margin European technology talent capabilities. Management Commentary and Outlook “In 2025, Atlantic navigated through a transitional period, taking decisive actions to realign our cost structure and stabilize operations,” said Jeffrey Jagid, Chief Executive Officer of Atlantic International Corp. “These dynamics were a key driver behind...

Continue reading

Biomerica Announces Medicare Administrative Contractor Confirmation of Individual Claim Review for inFoods® IBS, Opening a Scalable Medicare Commercialization Pathway

Company and Laboratory Partner Believe Properly Documented Claims Are Positioned for Payment Under Existing $300 CMS Reimbursement RateThe Medicare Administrative Contractor (MAC) responsible for processing inFoods® IBS claims has confirmed to Biomerica’s certified laboratory partner that the test will be reviewed on an individual, claim-by-claim basis under Medicare’s standard claims approval process. The Company’s laboratory partner believes that properly documented claims — with appropriate diagnosis codes and evidence of medical necessity — are eligible for payment under existing $300 CMS payment rate. The inFoods® IBS test holds a dedicated CPT® Proprietary Laboratory Analyses (PLA) code and a CMS-established national payment rate of $300, prerequisites for Medicare claims submissions. Payment rates apply to claims approved by...

Continue reading

ALL ACCOR ANNOUNCES THE RETURN OF THE “DREAM TOURNAMENT”

Press releaseApril 16th, 2026ALL ACCOR ANNOUNCES THE RETURN OF THE“DREAM TOURNAMENT” A UNIQUE OPPORTUNITY TO EXPERIENCE A DAYIN THE SHOES OF A PARIS SAINT-GERMAIN PLAYERALL Accor, Accor’s booking platform and loyalty programme, announces the return of the Dream Tournament, an exclusive experience taking place on May 18th at the Parc des Princes, the home of Paris Saint-Germain. On this occasion, ALL Accor members from all around the world, along with a few lucky contests winners, will have the unique opportunity to play alongside a selection of iconic Paris Saint-Germain Legends, including Blaise Matuidi, Javier Pastore, Mamadou Sakho, Guillaume Hoarau, and Pedro Miguel Pauleta. Relentless midfielders, creative playmakers, prolific strikers and emblematic defenders, these standout figures in the club’s recent history have left a lasting...

Continue reading

JAKKS Pacific, Inc. Announces First Quarter 2026 Earnings Call

SANTA MONICA, Calif., April 16, 2026 (GLOBE NEWSWIRE) — April 16, 2026 — JAKKS Pacific, Inc. (NASDAQ: JAKK) will announce its first quarter 2026 financial results on Thursday, April 30, 2026 after the close of the stock market. The Company invites analysts, investors and media to listen to a teleconference scheduled for 5:00 p.m. ET / 2:00 p.m. PT on April 30, 2026 to discuss the results, and potentially future plans and prospects. A live webcast of the call will be available on the “Investor Relations” page of the Company’s website at www.jakks.com/investors. To access the call by phone, please go to this link (1Q26 Registration link), and you will be provided with dial-in details. To avoid delays, we encourage participants to dial into the conference call ten minutes ahead of the scheduled start time. A replay of the webcast...

Continue reading

BIO-key Expects 50% Increase in First Half Revenues, Driving Profitability in the Period

HOLMDEL, N.J., April 16, 2026 (GLOBE NEWSWIRE) — BIO-key® International, Inc. (Nasdaq: BKYI), a global leader in Identity and Access Management (IAM) and biometric authentication technologies, previewed today its business outlook for the first half of 2026 (1H’26) ending June 30, 2026, supported by building software license momentum and strength in hardware revenues. Expected 1H’26 Results:1H’26 revenues expected to grow 50% to approximately $5M vs. $3.3M in 1H’25 Positive net income expected in 1H’26 vs. $1.9M net loss in 1H’25 Cash position at the close of 1H’26 is expected to remain in line with $2.7M at year-end 2025Q1’26 & Q2’26 Expected Revenues:Q1’26 revenues expected to grow 37% to $2.2M vs. $1.6M in Q1’25 Q2’26 revenues expected to grow 65% to $2.8M vs. $1.7M in Q2’25BIO-key’s improved 1H’26 results reflect...

Continue reading

Ealixir Reports Full Year 2025 Results

Revenue and Gross Profit Increases Reflect Operational Improvements and Service Expansion MIAMI, April 16, 2026 (GLOBE NEWSWIRE) — Ealixir, Inc. (OTCID: EAXR) (“Ealixir” or the “Company”), an internet technology company specializing in online reputation management services for the AI era, today announced financial results for the twelve-month period ended December 31, 2025. “2025 was a year of meaningful growth and progress, as we strengthened our foundation across the full client lifecycle, from client intake and pricing discipline through to delivery and long-term digital identity support,” said Eleonora Ramondetti, Chief Executive Officer of Ealixir. “These improvements resulted in enhanced conversion and assessment capabilities as we expanded our global footprint, resulting in a 7% growth in year-over-year revenue generation...

Continue reading

George Weston Limited Commits $600 Million Equity Investment to Choice Properties REIT in Connection with Its Proposed Acquisition of Real Estate Assets from First Capital REIT

Not for distribution to U.S. News Wire Services or dissemination in the United States TORONTO, April 16, 2026 (GLOBE NEWSWIRE) — George Weston Limited (“GWL”) (TSX: WN) today announced it has committed to a $600 million equity investment in Choice Properties REIT (“Choice Properties”) (TSX: CHP.UN). The commitment has been made in connection with Choice Properties’ expected acquisition of approximately $5.0 billion of assets from First Capital REIT (“First Capital”), announced earlier today (the “Acquisition”). Richard Dufresne, President and Chief Financial Officer of GWL, said, “We are pleased to support Choice Properties in this strategic and defining transaction. This Acquisition is expected to enhance the quality of Choice Properties’ portfolio and strengthen its long-term growth profile. Our continued majority...

Continue reading

Clarification – distribution of the press release dated Thursday 16 April 2025

The message distributed earlier today included the word “Correction” in its subject line. We confirm that this reference results solely from a technical redistribution to our internal distribution list and is in no way related to the content of the press release. The press release that you received today remains strictly unchanged from the version published this morning at 7:00 on our website.

Continue reading

Alterity Therapeutics Announces Late-Breaker Oral Presentation at the American Academy of Neurology Annual Meeting

MELBOURNE, Australia and SAN FRANCISCO, April 16, 2026 (GLOBE NEWSWIRE) — Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that Daniel Claassen, M.D., M.S., Professor of Neurology at Vanderbilt University Medical Center and Chief Medical Advisor for Alterity, will deliver an oral presentation during a Late Breaking Session at the American Academy of Neurology (AAN) Annual Meeting taking place April 18-22, 2026 in Chicago, IL, USA.Session:  Late-breaking Science 2Type: Oral PresentationTitle: ATH434 Demonstrates Disease-Modifying Signal in Multiple System Atrophy Using the MuSyCA Composite ScaleDate/Time: Tuesday, April 21, 2026, 6:21 PM CTAbout Alterity Therapeutics...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.